Pasar al contenido principal

ESTUDIO EN PROFUNDIDAD DE 3 VIAS DE SEÑALIZACION BIOLOGICAMENTE DISTINTAS QUE CONDUCEN A STEMNESS, CELL DESDIFERENCIACION Y RESISTENCIA A TERAPIA EN CANCER.

PID2021-122629OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Multitasker Protein: A Look at the Multiple Capabilities of NUMB

  • Ortega-Campos, Sara M.
  • García-Heredia, José Manuel
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., NUMB, a plasma membrane-associated protein originally described in Drosophila, is involved in determining cell function and fate during early stages of development. It is secreted asymmetrically in dividing cells, with one daughter cell inheriting NUMB and the other inheriting its antagonist, NOTCH. NUMB has been proposed as a polarizing agent and has multiple functions, including endocytosis and serving as an adaptor in various cellular pathways such as NOTCH, Hedgehog, and the P53-MDM2 axis. Due to its role in maintaining cellular homeostasis, it has been suggested that NUMB may be involved in various human pathologies such as cancer and Alzheimer’s disease. Further research on NUMB could aid in understanding disease mechanisms and advancing the field of personalized medicine and the development of new therapies., This work was supported by different grants: Grants RTI2018-097455-B-I00 and PID2021-122629OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”. Additional grants from CIBER de Cáncer (CB16/12/00275), from Consejeria de Salud (PI-0397-2017) and Project P18-RT-2501 from 2018 competitive research projects call within the scope of PAIDI 2020—80% co-financed by the European Regional Development Fund (ERDF) from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía. Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR for supporting this work., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Interactions of circadian clock genes with the hallmarks of cancer

  • Ortega-Campos, Sara M.
  • Verdugo-Sivianes, Eva M.
  • Amiama-Roig, Ana
  • Blanco, José Ramón
  • Carnero, Amancio
The molecular machinery of the circadian clock regulates the expression of many genes and processes in the organism, allowing the adaptation of cellular activities to the daily light-dark cycles. Disruption of the circadian rhythm can lead to various pathologies, including cancer. Thus, disturbance of the normal circadian clock at both genetic and environmental levels has been described as an independent risk factor for cancer. In addition, researchers have proposed that circadian genes may have a tissue-dependent and/or context-dependent role in tumorigenesis and may function both as tumor suppressors and oncogenes. Finally, circadian clock core genes may trigger or at least be involved in different hallmarks of cancer. Hence, expanding the knowledge of the molecular basis of the circadian clock would be helpful to identify new prognostic markers of tumorigenesis and potential therapeutic targets., This work was supported by Grants RTI2018–097455-B-I00 and PID2021-122629OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”. Additional grants from CIBER de Cáncer (CB16/12/00275), from Consejeria de Salud (PI-0397-2017) and Project P18-RT-2501 from 2018 competitive research projects call within the scope of PAIDI 2020—80% co-financed by the European Regional Development Fund (ERDF) from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía. Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR for supporting this work. EMV-S was funded by a postdoctoral contract from Consejeria of Transformacion Economica, Industria, Conocimiento, y Universidades of the Junta de Andalucia, Spain (No. CTEICU/PAIDI 2020, DOC_01655)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tfcp2l1 as a central integrator of hypoxia, dedifferentiation, and tumor progression

  • Clemente-González, Cynthia
  • Carnero, Amancio
The gene Tfcp2l1 has emerged as a central player linking key processes in cancer biology: hypoxia, immortalization, dedifferentiation, and tumor progression. Originally identified for its role in maintaining pluripotency in embryonic stem cells, Tfcp2l1 has been found to reappear in various cancers, especially under conditions of low oxygen (hypoxia). Hypoxia, a common feature of solid tumors, triggers the reactivation of developmental genes like Tfcp2l1, enabling cancer cells to dedifferentiate and adopt stem cell-like properties. This dedifferentiation facilitates the immortalization of cells—allowing them to bypass senescence and continue proliferating. Tfcp2l1 contributes to this process by regulating transcriptional networks that suppress differentiation and support self-renewal. Its expression correlates with poor prognosis in several cancers, highlighting its potential role in tumor aggressiveness and resistance to therapy. By acting at the intersection of cellular plasticity, stress adaptation, and oncogenic transformation, Tfcp2l1 may serve as a molecular bridge linking early developmental programs with malignant behaviors. Understanding how Tfcp2l1 integrates signals from hypoxic stress and drives dedifferentiation could uncover new therapeutic targets aimed at reversing or halting tumor progression., This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I, Agencia Estatal deInvestigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER,UE): PID2021-122629OB-I00, PID2024-155394OB-I00 and RED2024-153635-T (iDIFFER network) grants from AEI-MICIU/ 10.13039/501100011033 and, by “ERDF A way of making Europe”, by the “European Union” or by the “European Union Next Generation EU/PRTR” from CIBER de Cáncer(CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union); from Consejería de Salud and from Consejería de Economía, Conocimiento, Empresas y Universidad de la Junta de Andalucía (DGP_PIDI_2024_00907). Special thanks to the AECC Foundation (Spanish Association of Cancer Research) for supporting this work (founding ref. GC16173720CARR)., Peer reviewed